Procaspase-3 Activation as an Anti-Cancer Strategy: Structure-Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and its Cellular Co-Localization with Caspase-3

Yazar: Peterson, Quinn P., Hsu, Danny C., Goode, David R., Novotny, Chris J., Totten, Ryan K., Hergenrother, Paul J.
Baskı/Yayın Bilgisi 2009

Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)

Yazar: Hsu, Danny C., Roth, Howard S., West, Diana C., Botham, Rachel C., Novotny, Chris J., Schmid, Steven C., Hergenrother, Paul J.
Baskı/Yayın Bilgisi 2011

Discovery and Canine Preclinical Assessment of a Non-Toxic Procaspase-3-Activating Compound

Yazar: Peterson, Quinn P., Hsu, Danny C., Novotny, Chris J., West, Diana C., Kim, Dewey, Schmit, Joanna M., Dirikolu, Levent, Hergenrother, Paul J., Fan, Timothy M.
Baskı/Yayın Bilgisi 2010

Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong

Yazar: Yuen, Man-Fung, Liu, Sze-Hang, Seto, Wai-Kay, Mak, Lung-Yi, Corman, Shelby L., Hsu, Danny C., Lee, Mary Y. K., Khan, Tsz K., Puenpatom, Amy
Yayımlandı Dig Dis Sci (2020)

Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1 in healthy dogs

Yazar: Lucas, Pamela W., Schmit, Joanna M., Peterson, Quinn P., West, Diana C., Hsu, Danny C., Novotny, Chris J., Dirikolu, Levent, Deorge, Daniel R., Garrett, Laura D., Hergenrother, Paul J., Fan, Timothy M.
Baskı/Yayın Bilgisi 2010

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

Yazar: Loong, Herbert H., Wong, Carlos K. H., Leung, Linda Kam Suet, Dhankhar, Praveen, Insinga, Ralph P., Chandwani, Sheenu, Hsu, Danny C., Lee, Mary Y. K., Huang, Min, Pellissier, James, Rai, Akanksha, Achra, Monika, Tan, Seng Chuen
Yayımlandı Pharmacoecon Open (2019)